Skye Bioscience has partnered with Arecor Therapeutics to develop a higher formulation of the former鈥檚 obesity聽candidate nimacimab, a cannabinoid receptor 1 (CB1)-inhibiting monoclonal antibody.
The partnership aims to leverage Arecor’s formulation technology platform, Arestat, to develop the formulation.
Skye will provide funding for the development activities of Arecor with the option to licence rights to nimacimab鈥檚 new formulation and related intellectual property, enabling further development and commercialisation of the product.
The antibody is currently being assessed in the Phase IIa CBeyond trial for obesity and overweight patients.
The trial also evaluates nimacimab in combination with a glucagon-like peptide-1 receptor (GLP-1R) agonist, Wegovy.
Data from the first 26-week treatment duration is expected in the late third quarter (Q3) or early fourth quarter (Q4) of 2025.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSkye Bioscience chief operating officer Tu Diep stated: 鈥淎pproved weight loss drugs have issues with tolerability and adherence, while the small molecule CB1 inhibitors raise concerns about cumulative exposure-related neuropsychiatric toxicities.
鈥淣imacimab already has an advantageous pharmacokinetic profile and to date it does not pose these issues. It has a potentially best-in-class half-life of 18 to 21 days – substantially longer than GLP-1-based therapies – and is being evaluated in a Phase IIa study with once-weekly dosing.
鈥淪erving our goal of continuous innovation, we are pleased to work with Arecor on the goal of further enhancing nimacimab to improve patient compliance and treatment outcomes.鈥�
Arecor鈥檚 Arestat platform is backed by a patent portfolio.
Arecor Therapeutics CEO Sarah Howell stated: 鈥淭his collaboration highlights the strength of our proprietary Arestat technology in enabling the development of enhanced therapeutic products that can improve patient outcomes and supports our strategy of bringing innovative medicines to market that address significant unmet patient needs in high-value markets.鈥�
